|
Friday, November 17, 2017
Print Current Session:
 |
|
|
Friday
SESSION 74:
MORE NEW DEVELOPMENTS IN CAROTID TOPICS RELATED TO MEDICAL TREATMENT, PLAQUE CHANGES WITH TREATMENT, CAS/CEA STROKE RISKS, POST CAS ISR AND VERTEBRAL ARTERY DISSECTIONS
Location: Grand Ballroom East, 3rd Floor
Moderators:Ross Naylor, MD, FRCS / James May, MD, MS, FRACS, FACS |
|
| SESSION 74 SCHEDULE | |
| 10:42 AM - 10:47 AM | Periprocedural Statins Decrease Stroke Rates And Early Cognitive Dysfunction After CEA For Asymptomatic Carotid Stenosis, And May Increase Long-Term Patient Survival: What Drug And Dose Is Best |
|
Presenter(s):E. Sander Connolly, MD / Eric J. Heyer, MD, PhD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 10:48 AM - 10:53 AM | What Is Optimal Medical Treatment For Patients With Carotid Stenosis: How Low Should LDL-C Go: Value Of Mediterranean And Nordic Diets |
|
Presenter(s):J. David Spence, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 10:54 AM - 10:59 AM | The Risk Of Stroke In Asymptomatic Carotid Stenosis Patients On Good Medical Management Is So Low That All Should Be Treated Medically: Stratification Of Risk Is Of Little Value: Is Stenosis Or Plaque Progression A Reason To Treat Asymptomatic Patients With CEA Or CAS |
|
Presenter(s):Henrik Sillesen, MD, DMSc Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 11:00 AM - 11:05 AM | How To Predict Procedural Stroke Risk With CEA For Asymptomatic Carotid Stenosis (The ACER Score): What Percentage Of Such Patients Should Undergo CEA Or CAS |
|
Presenter(s):Richard Bulbulia, MA, MD, FRCS Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 11:06 AM - 11:11 AM | How To Decrease The Risks Of CAS: What New Techniques And Devices May Help: How Does The Double Filter Paladin Device (Contego Medical) Work |
|
Presenter(s):William A. Gray, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 11:12 AM - 11:17 AM | CAS In The Real World Has Higher Stroke And Death Rates Than In Reported Trials: National Registry Data Proves It In Both Symptomatic And Asymptomatic Patients |
|
Presenter(s):Kosmas I. Paraskevas, MD / Ross Naylor, MD, FRCS Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 11:18 AM - 11:23 AM | Panel Discussion |
| Moderator(s): Wesley S. Moore, MD / Enrico Ascher, MD | |
| 11:24 AM - 11:29 AM | Strokes (Clinical And Subclinical) After CAS And Other Interventional Procedures Have Much Greater Cognitive Deficits Than Previously Thought – Even With Full Neurological Recovery: What Are The Implications |
|
Presenter(s):L. Nelson Hopkins, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 11:30 AM - 11:35 AM | Periprocedural Statin Usage Reduces Mortality After CAS And Promotes Recovery When Complications (Stroke And MI) Occur |
|
Presenter(s):Mahmoud B. Malas, MD, MHS Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 11:36 AM - 11:41 AM | The Restenosis Rate After CAS Is Probably Higher Than After CEA In The RCTs: When Should Restenosis Be Treated Invasively |
|
Presenter(s):Ali F. AbuRahma, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 11:42 AM - 11:47 AM | Variations In National Trends For CEA And CAS Indication, Usage And Outcomes In Low And High Risk Patients: What Are The Implications |
|
Presenter(s):Mohammad H. Eslami, MD, MPH Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 11:48 AM - 11:53 AM | Vertebral Artery Dissections: Etiology, Diagnosis And How To Treat Them |
|
Presenter(s):Mark H. Wholey, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 11:54 AM - 12:00 PM | Panel Discussion |
| 12:00 PM - 1:00 PM | Lunch Break – 2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 74 | |
| previous | next |